Oncología médica
Especialidad
Fondazione IRCCS Istituto Nazionale dei Tumori
Milán, ItaliaPublicaciones en colaboración con investigadores/as de Fondazione IRCCS Istituto Nazionale dei Tumori (5)
2020
-
Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study
International Journal of Cancer, Vol. 147, Núm. 5, pp. 1315-1324
2011
-
Evidence for a link between TNFRSF11A and risk of breast cancer
Breast Cancer Research and Treatment, Vol. 129, Núm. 3, pp. 947-954
-
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer
PLoS Biology, Vol. 9, Núm. 11
2007
-
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
Lancet, Vol. 369, Núm. 9561, pp. 559-570
2004
-
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
New England Journal of Medicine, Vol. 350, Núm. 11, pp. 1081-1092